paclitaxel has been researched along with etravirine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Choi, J; Chung, JS; Ha, JS; Jang, WB; Kim, JH; Kim, YJ; Kwon, SM; Lee, DH; Ly, TTG; Min, SH; Rethineswaran, VK; Van Le, TH; Yang, JS; Yun, J | 1 |
1 review(s) available for paclitaxel and etravirine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for paclitaxel and etravirine
| Article | Year |
|---|---|
Inhibitory Effect of Etravirine, a Non-Nucleoside Reverse Transcriptase Inhibitor, via Anterior Gradient Protein 2 Homolog Degradation against Ovarian Cancer Metastasis.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mucoproteins; Neoplasm Metastasis; Nitriles; Oncogene Proteins; Ovarian Neoplasms; Paclitaxel; Proteolysis; Pyrimidines; Reverse Transcriptase Inhibitors; Xenograft Model Antitumor Assays | 2022 |